Series C closed July 2026, led by Index Ventures.[1][2]

post-money valuation is not publicly disclosed.

Named investors include OpenAI, Thrive Capital, Dimension, Menlo Ventures, Oak HC/FT, General Catalyst, Index Ventures, Kleiner Perkins, Sequoia Capital, Bain Capital Ventures, Battery Ventures, Baillie Gifford, BDT & MSD Partners, Sapphire Ventures, avra, Glade Brook Capital Partners, Avenir, Lachy Groom, Yosemite, Neo, SV Angel, Emerson Collective, DST Global Partners, DCVC, Fred Ehrsam.[1][2][4][5]

Joshua Meier, Co-Founder and CEO[5][6][7][13][14]

Jack Dent, Co-Founder[5][6][7][13][14]

Matthew McPartlon, Co-Founder[5][6][7][13][14]

Jacques Boitreaud, Co-Founder[5][6][7][13][14]

Danny Geisz, Founding AI Scientist[2][5][13]

Paul Wollenhaupt, Founding AI Research Scientist[2][5][13]

Mikael Dolsten, Board Member (former Pfizer Chief Scientific Officer)[2][5][13]

Absci · absci.com · Same buyer and job: Joshua Meier was Chief AI Officer at Absci before founding Chai, and both sell AI-driven antibody design to pharma discovery teams.[7]

Aqemia · aqemia.com · Same buyer and job: Jacques Boitreaud was Machine Learning Lead at Aqemia before co-founding Chai, and both sell AI-driven molecular design to pharma.[6]

Isomorphic Labs · isomorphiclabs.com · Same buyer and job: both sell frontier AI molecular design models to large pharma for drug discovery, competing for the same pharma R&D budget.

The customer proof is company-sourced only. No independent source in this ledger confirms it.[1][2]

Ask for one referenceable production customer.

Not a recommendation. The first thing this ledger cannot answer.

Filled in the side panel for invited readers. This card carries sourced facts only.